BTTC12-01: A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

8623-CTO
Cancer - Brain
Principal Investigator: Tobias Walbert, MD

The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied.

The study doctor can explain how the study drugs are designed to work.

  1. Patients must be 18 years or older.
  2. Patients with histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS). Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a GBM or GS is made. Patients must have evidence of progression of the GBM or GS on MRI or CT scan.

Please contact us for a full list of eligibility criteria.

Open
Tiffany Pearce
(313) 916-1784